LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Diagnostic Tests Evaluated for Human Plasmodium knowlesi

By LabMedica International staff writers
Posted on 27 Mar 2014
Print article
Image: A mature schizont of Plasmodium knowlesi in a thin blood film of a malaria patient (Photo courtesy of US Centers of Disease control and Prevention).
Image: A mature schizont of Plasmodium knowlesi in a thin blood film of a malaria patient (Photo courtesy of US Centers of Disease control and Prevention).
Rapid diagnostic tests (RDTs) have been evaluated for the diagnosis of Plasmodium knowlesi, a malaria parasite of Southeast Asian macaques, Macaca fascicularis that infects humans and can cause fatal malaria.

Until recently only four types of Plasmodium (P. falciparum, P. vivax, P. malariae, and P. ovale) were known to cause malaria in humans, however, a fifth species, P. knowlesi, has been identified as a cause of human malaria in almost all countries in Southeast Asia. P. knowlesi is difficult to diagnose by microscopy because of morphological similarity to P. malariae.

Scientists at the Universiti Malaysia Sarawak, (Malaysia) and their international colleagues diagnosed by microscopy 40 malaria patients, 28 P. knowlesi, 10 P. vivax, and 2 P. falciparum. Patient blood samples were used to determine parasitaemia by microscopy, confirm the Plasmodium species present by polymerase chain reaction (PCR) and evaluate three RDTs using frozen blood samples from 41 P. knowlesi malaria patients.

A large number of RDTs are available for malaria diagnosis, including the three used in this study: OptiMAL-IT (DiaMed; Mississauga, ON, Canada), BinaxNOW Malaria (Alere; Waltham, MA, USA), and Paramax-3 malaria Pf/Pv/Pan (Zephyr Biomedical Systems; Goa, India). The sensitivity of each RDT was calculated with nested PCR results as the reference standard.

OptiMAL-IT was the most sensitive RDT, with a sensitivity of 71% (20/28) for fresh and 73% (30/41) for frozen P. knowlesi samples. However, the test was not specific and P. knowlesi samples cross-reacted with the P. falciparum LDH test reagent in 18 of the 20 fresh samples identified. BinaxNOW Malaria correctly detected non-P. falciparum malaria in P. knowlesi samples but was the least sensitive, detecting only 29% (8/28) of fresh and 24% (10/41) of frozen samples. The Paramax-3 RDT tested positive for P. vivax with PCR-confirmed P. knowlesi samples with sensitivities of 40% (10/25) with fresh and 32% (13/41) with frozen samples. All RDTs correctly identified P. falciparum- and P. vivax-positive controls with parasitaemias above 2,000 parasites/μL blood.

The authors concluded that the sensitivity of detection of P. knowlesi by the three RDTs evaluated is low compared with microscopy. Cross-reactivity is common between P. knowlesi-infected blood and both the P. falciparum-detecting antibody used in the OptiMAL-IT test and the P. vivax-detecting antibody used in the Paramax-3 test. Since not all species of malaria warrant the same level of medical care, misidentification can result in mismanagement, especially when the potentially severe knowlesi malaria is misdiagnosed as vivax malaria. The study was published on February 18, 2014, in the Malaria Journal.

Related Links:

Universiti Malaysia Sarawak
DiaMed
Alere


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.